covid
Buscar en
Progresos de Obstetricia y Ginecología
Toda la web
Inicio Progresos de Obstetricia y Ginecología Elevada incidencia de premutaciones en el gen FMR1 en mujeres españolas con fal...
Journal Information
Vol. 44. Issue 6.
Pages 261-266 (January 2001)
Share
Share
Download PDF
More article options
Vol. 44. Issue 6.
Pages 261-266 (January 2001)
Full text access
Elevada incidencia de premutaciones en el gen FMR1 en mujeres españolas con fallo ovárico prematuro
High incidence of premutations in the FMR1 gene in Spanish women with premature ovarian failure
Visits
4693
M. Durána, J. Mallolasb, M. Riféb, S. Castellvíb, D. Jiménezb, A. Sánchezb,c, M. Milàb,c,
Corresponding author
mmila@clinic.ub.es

Correspondencia: Servicio de Genética. Hospital Clínic.Villarroel, 170. 08036 Barcelona
a Servicios de Ginecología. Hospital Clínic. Barcelona
b Genética. Hospital Clínic. Barcelona
c Institut d'Investigacions Biomèdiques August Pi i Sunyer.(IDIBAPS). Barcelona
This item has received
Article information
Resumen
Objetivo

Valorar la necesidad de incluir el estudio del gen FMR1 y/o FMR2, dos genes responsables de retraso mental, en los protocolos de estudio de las mujeres que presentan fallo ovárico prematuro (FOP) de causa idiopática

Sujetos y métodos

Se ha estudiado la zona repetitiva CGG de los genes FMR1 y FMR2 a 45 mujeres que consultaban al Servicio de Ginecología o Genética del Hospital Clínic de Barcelona por presentar menopausia precoz

Resultados

En 2 mujeres (4,4%) se ha detectado una expansión del triplete CGG en el gen FMR1 correspondiente a una premutación. No se ha detectado ninguna variación del rango de la normalidad en el triplete CGG en el gen FMR2. La incidencia de mujeres portadoras de premutación en el gen FMR1 entre la población de mujeres que presentan menopausia precoz es 11 veces mayor que la de la población general (1/246)

Conclusiones

Un tercio de los casos de FOP son familiares, lo cual indica la necesidad de los estudios genéticos. Dada la elevada incidencia de portadoras de premutación en el gen FMR1 en la población de mujeres con FOP, el riesgo que esto comporta para su descendencia (un 50% de riesgo de tener un hijo con retraso mental) y la facilidad del estudio molecular, se recomienda incluir el estudio del gen FMR1 en los protocolos genéticos de FOP

Palabras clave:
Fallo ovárico prematuro
Gen FMR1
Gen FMR2
Retraso mental
Abstract
Objective

To evaluate the possible incorporation of the study of FMR1 and/or FMR2, two genesresponsible for mental retardation, in clinical procedures for women presenting premature ovarian failure (POF) of idiopathic cause

Patients And Methods

The CGG repeat expansion in the FMR1 and FMR2 genes was studied in 45 women referred for POF in the Gynecology or Genetics Service of the Hospital Clínic of Barcelona

Results

A CGG premutation in the FMR1 gene was detected in 2 women (4.4%). No alterations were detected in the FMR2 gene. The incidence of FMR1 premutation carriers among women with POF was 11-fold higher than that of the general population (1/246)

Conclusions

One third of the POF cases are familial emphasizing the importance of genetic studies. Since we detected a high incidence of premutation carriers of the FMR1 gene among POF women, taking into account the risk for their offspring (50% of having a son with mental retardation), and the simplicity of the molecular test, we recommend including the analysis of the FMR1 gene in the clinical procedures for POF

Keywords:
Premature ovarian failure
FMR1 gene
FMR2 gene
Mental retardation
Full text is only aviable in PDF
Bibliografía
[1.]
R.S. Davis.
Premature ovarian failure.
Maturitas, 23 (1996), pp. 1-8
[2.]
C.B. Coulam, S.C. Adamson, J.F. Annergers.
Incidence of premature ovarian failure.
Obstet Gynecol, 67 (1986), pp. 604-606
[3.]
M.G. Tibiletti, G. Testa, W. Vegetti, F. Alagna, M. Taborelli, L. Dalpra, et al.
The idiopathic forms of premature menopause and early menopause show the same genetic pattern.
Hum Reprod, 14 (1999), pp. 2731-2734
[4.]
C.J. Davis, R.M. Davison, N.N. Payne, C.H. Rodeck, G.S. Conway.
Female Sex prepònderance for idiopathic familial premature ovarian failure suggest an X chromosome defect.
Hum Reprod, 15 (2000), pp. 2418-2422
[5.]
C.M. Powell, R.T. Taggart, T.C. Drumheller, D. Wangsa, C. Qian, L.M. Nelson, et al.
Molecular and cytogenetic studies of an X; autosome translocation in a patient with premature ovarian failure and review of the literature.
Am J Med Genet, 52 (1994), pp. 19-26
[6.]
C. Sala, G. Arrigo, G. Torri, F. Martinazzi, P. Riva, L. Larizza, et al.
Eleven X chromosome breakpoints associated with premature ovarian failure (POF) map to a 15-Mb YAC contig spanning Xq21.
Genomics, 40 (1997), pp. 123-131
[7.]
D.J. Allingham-Hawkins, R. Babul-Hirji, D. Chitayat, J.J. Holden, K.T. Yang, C. Lee, et al.
Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study-preliminary data.
Am J Med Genet, 83 (1999), pp. 322-325
[8.]
G. Turner, T. Webb, S. Wake, H. Robinson.
Prevalence of fragile X syndrome.
[9.]
I. Oberle, F. Rousseau, D. Heitz, C. Kretz, D. Devys, A. Hanauer, et al.
Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome.
Science, 252 (1991), pp. 1097-1102
[10.]
M. Milà, H. Kruyer, G. Glover, A. Sánchez, P. Carbonell, S. Castellvi- Bel, et al.
Molecular analysis of the (CGG)n expansion in the FMR-1 gene in 59 Spanish fragile X syndrome families.
Hum Genet, 94 (1994), pp. 395-400
[11.]
S.J. Knight, A.V. Flannery, M.C. Hirst, L. Campell, Z. Christodoulou, S.R. Phelps, et al.
Cell, 74 (1993), pp. 127-134
[12.]
Brown WT. The Fraxe syndrome: is it time for routine screening? Am J Hum Genet; 58: 903
[13.]
A. Murray, J. Webb, S. Grimley, G. Conway, P. Jacobs.
Studies of FRAXA and FRAXE in women with premature ovarian failure.
J Med Genet, 35 (1998), pp. 637-640
[14.]
M.L. Giovannucci Uzielli, S. Guarducci, E. Lapi, A. Cecconi, U. Ricci, G. Ricotti, et al.
Premature ovarian failure (POF) and fragile X premutation females: from POF to fragile X carrier identification, from fragile X carrier to POF association data.
Am J Med Genet, 84 (1999), pp. 300-303
[15.]
A. Marozzi, W. Vegetti, E. Manfredini, M.G. Tibiletti, G. Testa, P.G. Crosignani, et al.
Association between idiopathic premature ovarian failure and fragile X premutation.
Hum Reprod, 15 (2000), pp. 197-202
[16.]
J. Mallolas, M. Duran, A. Sánchez, D. Jiménez, S. Castellví-Bel, M. Rifé, et al.
Implications of the FMR1 gene in menopause: study of 147 Spanish women.
Menopause, 8 (2001), pp. 106-110
[17.]
S.A. Miller, D.D. Dykes, H.F. Polesky.
A simple salting out procedure for extracting DNA from human nucleated cells.
Nucleic Acids Res, 16 (1988), pp. 1215
[18.]
M. Milà, A. Sánchez, C. Badenas, C. Brun, D. Jiménz, X. Villa, et al.
Screening for FMR1 and FMR2 mutations in 222 individuals from Spanish special schools: identification of a case of FRAXEassociated mental retardation.
Hum Genet, 100 (1997), pp. 503-507
[19.]
G.S. Conway, S. Hettiarachchi, A. Murray, P.A. Jacobs.
Fragile X premutations in familial premature ovarian failure.
Lancet, 346 (1995), pp. 309-310
[20.]
M. Ryynanen, S. Heinonen, M. Makkonen, E. Kajanoja, A. Mannermaa, K. Pertti.
Feasibility and acceptance of screening for fragile X mutations in low-risk pregnancies.
Eur J Hum Genet, 7 (1999), pp. 212-216
[21.]
D. Bachner, A. Manca, P. Steinbach, et al.
Enhanced expression of the murina FMR1 gene during germ cell proloferation suggests a special funtion in both male and female gonads.
Hum Mol Genet, 2 (1993), pp. 2043-2050
[22.]
J.P. Fryns.
The female and the fragile X. A study of 144 obligate female carriers.
Am J Med Genet, 23 (1986), pp. 157-169
[23.]
G. Turner, H. Robinson, S. Wake, N. Martin.
Dizygous twinning and premature menopause in fragile X syndrome.
Lancet, 344 (1994), pp. 1500
[24.]
N.G. Martin, S.C. Healey, T.S. Pangan, A.C. Heath, G. Turner.
Do mothers of dizygotic twins have earlier menopause?.
A role for fragile X? Am J Med Genet, 69 (1997), pp. 114-116
Copyright © 2001. Sociedad Española de Ginecología y Obstetricia
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos